Cutaneous Adverse Effects Associated with Sorafenib Therapy (Nexavar(R), BAY 43-9006).
- Author:
Ji Ho PARK
1
;
Song KIM
;
Sun Chul CHOI
;
Eil Soo LEE
;
Jun Mo YANG
Author Information
1. Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jmyang@smc.samsung.co.kr
- Publication Type:Case Report
- Keywords:
Acral erythema;
Skin rash;
Sorafenib
- MeSH:
Adult;
Alopecia;
Bays;
Carcinoma, Hepatocellular;
Disease Progression;
Erythema;
Exanthema;
Humans;
Melanoma;
Niacinamide;
Phenylurea Compounds;
Protein-Tyrosine Kinases
- From:Korean Journal of Dermatology
2008;46(1):141-143
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sorafenib (Nexavar(R), BAY 43-9006) is a new oral multi-targeted tyrosine kinase inhibitor developed to delay disease progression in advanced solid organ malignancies and metastatic melanoma. Among the many reported toxicities attributed to sorafenib, dermatologic events, such as skin rash, acral erythema, alopecia and xerosis are the most frequently observed side effects. Recently, we experienced a case of a 41-year-old man who presented with generalized maculopapular erythematous eruptions, and acral erythema after sorafenib treatment for his metastatic hepatocellular carcinoma. Herein, we report the case and discuss the undesirable side effects of sorafenib.
